{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:06:28Z","timestamp":1783998388039,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272668"],"award-info":[{"award-number":["82272668"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304541"],"award-info":[{"award-number":["82304541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221036"],"award-info":[{"award-number":["BK20221036"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting dysregulated glutamine metabolism via ASCT2 inhibition has therapeutic potential in cancer, but its clinical translation is hindered by tumor metabolic heterogeneity and the lack of predictive biomarkers. This study aims to define genetic determinants of ASCT2 inhibitor sensitivity and uncover compensatory resistance mechanisms to enable precision therapeutic strategies. We systematically evaluated ASCT2 inhibitor responses across molecular subtypes of breast cancer via in vitro and in vivo models. Mechanistic studies integrated transcriptomics, metabolomics, and functional validation of candidate pathways. Using genetic and pharmacological tools, including TP53 isogenic lines and ASCT2 inhibitors, we mapped the metabolic compensation networks. This approach revealed that TP53-mutant triple-negative carcinomas were more sensitive to ASCT2 monotherapy than any other subtype. In TP53 wild-type tumors, ASCT2 inhibition triggered SLC7A3-mediated arginine uptake, destabilizing the CASTOR1-GATOR2 complex to sustain mTORC1-driven proliferation. Cotargeting ASCT2 and SLC7A3 overcame resistance in TP53 wild-type models, inducing metabolic collapse and tumor reduction. This work establishes the TP53 mutational status as a potential predictive biomarker for ASCT2 inhibitor responsiveness and defines the SLC7A3-arginine-mTORC1 axis as a targetable compensatory pathway. Therefore, we propose a genotype-guided therapeutic strategy, recommending ASCT2 monotherapy for TP53-mutant tumors and combined ASCT2 and SLC7A3 inhibition for TP53 wild-type cancers. These findings advance precision in targeting glutamine metabolism while providing a blueprint to counter adaptive resistance through rational drug combinations.<\/jats:p>","DOI":"10.1038\/s41419-026-08814-x","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:19:42Z","timestamp":1779347982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TP53 mutations in triple-negative breast cancer cells confer sensitivity to ASCT2 inhibition via arginine uptake"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaodan","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-8218","authenticated-orcid":false,"given":"Zizhang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-4197","authenticated-orcid":false,"given":"Shengtao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9103-7969","authenticated-orcid":false,"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-1081","authenticated-orcid":false,"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"8814_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15136-9","volume":"11","author":"M Kodama","year":"2020","unstructured":"Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020;11:1320. https:\/\/doi.org\/10.1038\/s41467-020-15136-9.","journal-title":"Nat Commun"},{"key":"8814_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013\u201321. https:\/\/doi.org\/10.1126\/science.aav2588.","journal-title":"Science"},{"key":"8814_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jare.2024.02.023","volume":"68","author":"J Li","year":"2025","unstructured":"Li J, Zhang D, Wang S, Yu P, Sun J, Zhang Y, et al. Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer. J Adv Res. 2025;68:341\u201357. https:\/\/doi.org\/10.1016\/j.jare.2024.02.023.","journal-title":"J Adv Res"},{"key":"8814_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/gutjnl-2024-332429","volume":"74","author":"Y Yang","year":"2025","unstructured":"Yang Y, Pei T, Liu C, Cao M, Hu X, Yuan J, et al. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+ myeloid cells to promote liver cancer progression. Gut. 2025;74:255\u201369. https:\/\/doi.org\/10.1136\/gutjnl-2024-332429.","journal-title":"Gut"},{"key":"8814_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101706","volume":"5","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Geng F, Mazik L, Yin X, Becker AP, Mohammed S, et al. Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma. Cell Rep Med. 2024;5:101706. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101706.","journal-title":"Cell Rep Med"},{"key":"8814_CR6","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.3390\/cancers15205082","volume":"15","author":"XD Lyu","year":"2023","unstructured":"Lyu XD, Liu Y, Wang J, Wei YC, Han Y, Li X, et al. A novel ASCT2 inhibitor, C118P, blocks glutamine transport and exhibits antitumour efficacy in breast cancer. Cancers. 2023;15:5082 https:\/\/doi.org\/10.3390\/cancers15205082.","journal-title":"Cancers"},{"key":"8814_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104844","volume":"158","author":"H Jiang","year":"2020","unstructured":"Jiang H, Zhang N, Tang T, Feng F, Sun H, Qu W. Target the human Alanine\/Serine\/Cysteine transporter 2(ASCT2): achievement and future for novel cancer therapy. Pharm Res. 2020;158:104844. https:\/\/doi.org\/10.1016\/j.phrs.2020.104844.","journal-title":"Pharm Res"},{"key":"8814_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11523-024-01054-z","volume":"19","author":"M Maris","year":"2024","unstructured":"Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, et al. ASCT2-targeting antibody\u2012drug conjugate MEDI7247 in adult patients with relapsed\/refractory hematological malignancies: a first-in-human, phase 1 study. Target Oncol. 2024;19:321\u201332. https:\/\/doi.org\/10.1007\/s11523-024-01054-z.","journal-title":"Target Oncol"},{"key":"8814_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49 https:\/\/doi.org\/10.1038\/s41392-024-02108-4.","journal-title":"Signal Transduct Target Ther"},{"key":"8814_CR10","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.3390\/ijms25147517","volume":"25","author":"K Dvir","year":"2024","unstructured":"Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25:7517 https:\/\/doi.org\/10.3390\/ijms25147517.","journal-title":"Int J Mol Sci"},{"key":"8814_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y, et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer. 2024;23:261. https:\/\/doi.org\/10.1186\/s12943-024-02165-x.","journal-title":"Mol Cancer"},{"key":"8814_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu L, Saunders K, Huang SP, Knutsdottir H, Martinez-Algarin K, Terrazas I, et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep Med. 2024;5:101511. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101511.","journal-title":"Cell Rep Med"},{"key":"8814_CR13","doi-asserted-by":"publisher","unstructured":"McDonough E, Barroso M, Ginty F, Corr DT. Modeling intratumor heterogeneity in breast cancer. Biofabrication. 2024;17. https:\/\/doi.org\/10.1088\/1758-5090\/ad9b50","DOI":"10.1088\/1758-5090\/ad9b50"},{"key":"8814_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4143\/crt.2023.1138","volume":"56","author":"S Kang","year":"2024","unstructured":"Kang S, Kim SB. HER2-low breast cancer: now and in the future. Cancer Res Treat. 2024;56:700\u201320. https:\/\/doi.org\/10.4143\/crt.2023.1138.","journal-title":"Cancer Res Treat"},{"key":"8814_CR15","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.3390\/cancers16173028","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Q, Fu H, Han Y, Li X, Zou Q, et al. ASCT2 regulates fatty acid metabolism to trigger glutamine addiction in basal-like breast cancer. Cancers. 2024;16:3028 https:\/\/doi.org\/10.3390\/cancers16173028.","journal-title":"Cancers"},{"key":"8814_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01863-9","volume":"22","author":"H Qayoom","year":"2024","unstructured":"Qayoom H, Haq BU, Sofi S, Jan N, Jan A, Mir MA. Targeting mutant p53: a key player in breast cancer pathogenesis and beyond. Cell Commun Signal. 2024;22:484. https:\/\/doi.org\/10.1186\/s12964-024-01863-9.","journal-title":"Cell Commun Signal"},{"key":"8814_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380. https:\/\/doi.org\/10.1038\/s41568-020-0262-1.","journal-title":"Nat Rev Cancer"},{"key":"8814_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ccell.2018.12.012","volume":"35","author":"J Kim","year":"2019","unstructured":"Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova D, et al. Wild-type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation. Cancer Cell. 2019;35:191\u2013203.e8. https:\/\/doi.org\/10.1016\/j.ccell.2018.12.012.","journal-title":"Cancer Cell"},{"key":"8814_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/0008-5472.CAN-19-0650","volume":"80","author":"I Kaymak","year":"2020","unstructured":"Kaymak I, Maier CR, Schmitz W, Campbell AD, Dankworth B, Ade CP, et al. Mevalonate pathway provides ubiquinone to maintain pyrimidine synthesis and survival in p53-deficient cancer cells exposed to metabolic stress. Cancer Res. 2020;80:189\u2013203. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0650.","journal-title":"Cancer Res"},{"key":"8814_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109820","volume":"77","author":"HW Chang","year":"2021","unstructured":"Chang HW, Lee M, Lee YS, Kim SH, Lee JC, Park JJ, et al. p53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cells. Cell Signal. 2021;77:109820. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109820.","journal-title":"Cell Signal"},{"key":"8814_CR21","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1016\/j.celrep.2019.02.037","volume":"26","author":"XH Lowman","year":"2019","unstructured":"Lowman XH, Hanse EA, Yang Y, Ishak Gabra MB, Tran TQ, Li H, et al. p53 promotes cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake. Cell Rep. 2019;26:3051\u20133060.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.02.037.","journal-title":"Cell Rep"},{"key":"8814_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.cmet.2018.07.005","volume":"28","author":"M Tajan","year":"2018","unstructured":"Tajan M, Hock AK, Blagih J, Robertson NA, Labuschagne CF, Kruiswijk F, et al. A role for p53 in the adaptation to glutamine starvation through the expression of SLC1A3. Cell Metab. 2018;28:721\u2013.e6. https:\/\/doi.org\/10.1016\/j.cmet.2018.07.005.","journal-title":"Cell Metab"},{"key":"8814_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21206-3","volume":"12","author":"T Li","year":"2021","unstructured":"Li T, Wang X, Ju E, da Silva SR, Chen L, Zhang X, et al. RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation. Nat Commun. 2021;12:1055. https:\/\/doi.org\/10.1038\/s41467-021-21206-3.","journal-title":"Nat Commun"},{"key":"8814_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41586-022-04939-z","volume":"607","author":"ML Valenstein","year":"2022","unstructured":"Valenstein ML, Rogala KB, Lalgudi PV, Brignole EJ, Gu X, et al. Structure of the nutrient-sensing hub GATOR2. Nature. 2022;607:610\u20136. https:\/\/doi.org\/10.1038\/s41586-022-04939-z.","journal-title":"Nature"},{"key":"8814_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.172017","volume":"926","author":"Z Gai","year":"2024","unstructured":"Gai Z, Hu S, He Y, Yan S, Wang R, Gong G, et al. L-arginine alleviates heat stress-induced mammary gland injury through modulating CASTOR1-mTORC1 axis-mediated mitochondrial homeostasis. Sci Total Environ. 2024;926:172017. https:\/\/doi.org\/10.1016\/j.scitotenv.2024.172017.","journal-title":"Sci Total Environ"},{"key":"8814_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.763902","volume":"8","author":"J Han","year":"2021","unstructured":"Han J, Li Q, Chen Y, Yang Y. Recent metabolomics analysis in tumor metabolism reprogramming. Front Mol Biosci. 2021;8:763902. https:\/\/doi.org\/10.3389\/fmolb.2021.763902.","journal-title":"Front Mol Biosci"},{"key":"8814_CR27","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.3390\/molecules26164824","volume":"26","author":"AA Alhusban","year":"2021","unstructured":"Alhusban AA, Albustanji S, Hamadneh LA, Shallan AI. High-performance liquid chromatography-tandem mass spectrometry method for correlating the metabolic changes of lactate, pyruvate and L-glutamine with induced tamoxifen-resistant MCF-7 cell line potential molecular changes. Molecules. 2021;26:4824 https:\/\/doi.org\/10.3390\/molecules26164824.","journal-title":"Molecules"},{"key":"8814_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac103","volume":"4","author":"ME El-Abtah","year":"2022","unstructured":"El-Abtah ME, Talati P, Dietrich J, Gerstner ER, Ratai EM. Magnetic resonance spectroscopic imaging for detecting metabolic changes in glioblastoma after anti-angiogenic therapy: a systematic literature review. Neurooncol Adv. 2022;4:vdac103. https:\/\/doi.org\/10.1093\/noajnl\/vdac103.","journal-title":"Neurooncol Adv"},{"key":"8814_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100797","volume":"59","author":"AC Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves AC, Richiardone E, Jorge J, Pol\u00f3nia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance - Clinical implications. Drug Resist Updat. 2021;59:100797. https:\/\/doi.org\/10.1016\/j.drup.2021.100797.","journal-title":"Drug Resist Updat"},{"key":"8814_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"key":"8814_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139542","volume":"131","author":"P Kadiyala","year":"2021","unstructured":"Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haase S, Alghamri MS, et al. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J Clin Investig. 2021;131:e139542. https:\/\/doi.org\/10.1172\/JCI139542.","journal-title":"J Clin Investig"},{"key":"8814_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41575-021-00486-6","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18:804\u201323. https:\/\/doi.org\/10.1038\/s41575-021-00486-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8814_CR33","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/ijc.34660","volume":"153","author":"ME Roche","year":"2023","unstructured":"Roche ME, Ko YH, Domingo-Vidal M, Lin Z, Whitaker-Menezes D, Birbe RC, et al. TP53 induced glycolysis and apoptosis regulator and monocarboxylate transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer. Int J Cancer. 2023;153:1671\u201383. https:\/\/doi.org\/10.1002\/ijc.34660.","journal-title":"Int J Cancer"},{"key":"8814_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.phymed.2018.12.011","volume":"57","author":"L Wang","year":"2019","unstructured":"Wang L, Liu Y, Zhao TL, Li ZZ, He JY, Zhang BJ, et al. Topotecan induces apoptosis via ASCT2-mediated oxidative stress in gastric cancer. Phytomedicine. 2019;57:117\u201328. https:\/\/doi.org\/10.1016\/j.phymed.2018.12.011.","journal-title":"Phytomedicine"},{"key":"8814_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/ncb3410","volume":"18","author":"M Pan","year":"2016","unstructured":"Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, et al. Regional glutamine deficiency in tumors promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol. 2016;18:1090\u2013101. https:\/\/doi.org\/10.1038\/ncb3410.","journal-title":"Nat Cell Biol"},{"key":"8814_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molcel.2013.02.008","volume":"50","author":"MA Reid","year":"2013","unstructured":"Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, Kong M. The B55\u03b1 subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell. 2013;50:200\u201311. https:\/\/doi.org\/10.1016\/j.molcel.2013.02.008.","journal-title":"Mol Cell"},{"key":"8814_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cmet.2023.12.003","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wu MJ, Lu WC, Li YC, Chang CJ, Yang JY. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. Cell Metab. 2024;36:193\u2013208.e8. https:\/\/doi.org\/10.1016\/j.cmet.2023.12.003.","journal-title":"Cell Metab"},{"key":"8814_CR38","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1158\/0008-5472.CAN-21-3868","volume":"82","author":"B Zhang","year":"2022","unstructured":"Zhang B, Peng H, Zhou M, Bao L, Wang C, Cai F, et al. Targeting BCAT1 combined with \u03b1-ketoglutarate triggers metabolic synthetic lethality in glioblastoma. Cancer Res. 2022;82:2388\u2013402. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3868.","journal-title":"Cancer Res"},{"key":"8814_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.bbabio.2016.12.003","volume":"1858","author":"V Zecchini","year":"2017","unstructured":"Zecchini V, Frezza C. Metabolic synthetic lethality in cancer therapy. Biochim Biophys Acta Bioenerg. 2017;1858:723\u201331. https:\/\/doi.org\/10.1016\/j.bbabio.2016.12.003.","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"8814_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-42118-6_4","volume":"207","author":"AL Hsieh","year":"2016","unstructured":"Hsieh AL, Dang CV. MYC, metabolic synthetic lethality, and cancer. Recent Results Cancer Res. 2016;207:73\u201391. https:\/\/doi.org\/10.1007\/978-3-319-42118-6_4.","journal-title":"Recent Results Cancer Res"},{"key":"8814_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13046-022-02240-5","volume":"41","author":"Z Yang","year":"2022","unstructured":"Yang Z, Liang SQ, Zhao L, Yang H, Marti TM, Heged\u00fcs B, et al. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. J Exp Clin Cancer Res. 2022;41:25 https:\/\/doi.org\/10.1186\/s13046-022-02240-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"8814_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4:101162. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101162.","journal-title":"Cell Rep Med"},{"key":"8814_CR43","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.3390\/cancers13122922","volume":"13","author":"RW Holloway","year":"2021","unstructured":"Holloway RW, Marignani PA. Targeting mTOR and glycolysis in HER2-positive breast cancer. Cancers. 2021;13:2922 https:\/\/doi.org\/10.3390\/cancers13122922.","journal-title":"Cancers"},{"key":"8814_CR44","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","volume":"28","author":"PI Poulikakos","year":"2022","unstructured":"Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of Braf in cancer therapy. Clin Cancer Res. 2022;28:4618\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2138.","journal-title":"Clin Cancer Res"},{"key":"8814_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bjd.19394","volume":"185","author":"X Bai","year":"2021","unstructured":"Bai X, Flaherty KT. Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect. Br J Dermatol. 2021;185:253\u201362. https:\/\/doi.org\/10.1111\/bjd.19394.","journal-title":"Br J Dermatol"},{"key":"8814_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/2159-8290.CD-18-0879","volume":"9","author":"O Maertens","year":"2019","unstructured":"Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, et al. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-mutant melanomas. Cancer Discov. 2019;9:526\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0879.","journal-title":"Cancer Discov"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08814-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:59:38Z","timestamp":1783997978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08814-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8814"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08814-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the authors listed have approved the enclosed manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"640"}}